Download PDF
CC BY-NC-ND 4.0 · Journal of Gastrointestinal Infections 2022; 12(02): 101-105
DOI: 10.1055/s-0042-1759738
Original Article

Sofosbuvir-Velpatasvir Full Dose in Chronic Hepatitis C in End-Stage Renal Disease: An Observational Study from a Himalayan Region

Aadil Ashraf 
1   Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, Telangana, India
,
Altaf Shah
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Muzafar Wani
3   Department of Nephrology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Mushtaq Khan
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
G.M. Gulzar
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Shaheena Parveen
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Jaswinder Singh
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
,
Hilal Dar
4   Government Medical College (GMC) Baramulla, Baramulla, Jammu and Kashmir, India
,
Nadeem Ahmad
2   Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura, Jammu and Kashmir, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints


Abstract

Background Treatment of chronic hepatitis C (CHC) in the setting of chronic kidney disease and end-stage renal disease (ESRD) is challenging.

Objectives We planned to evaluate the efficacy and safety of full dose of combination of sofosbuvir-velpatasvir in the treatment of CHC in patients with ESRD or those on maintenance hemodialysis.

Methods The prospective observational study was conducted in a tertiary care center in North India where all patients with chronic kidney disease (CKD) were assessed. Those with hepatitis C virus (HCV) antibody positivity underwent testing for HCV ribonucleic acid and were treated if eligible. Full dose of sofosbuvir-velpatasvir was administered daily for 12 weeks (or 24 weeks for decompensated liver disease).

Results Of the 162 patients (mean age: 43.08 ± 12.08 years, 114 males), 125 were on regular hemodialysis. Twenty-four (15%) had evidence of liver cirrhosis, out of which four patients had evidence of decompensation. One hundred forty-two patients (87.6%) had an early virological response. Most patients, 160 (98.7%), obtained end of therapy viral clearance and sustained virological response at 12 weeks after therapy. Two patients died, and rest of the patients completed therapy. The adverse effects noticed were nausea (20%), vomiting (18%), headache (10%), and weakness (7%).

Conclusion A combination of sofosbuvir and velpatasvir is effective and safe in treating CHC in the setting of CKD.

Keywords

hepatitis C - cirrhosis - chronic kidney disease - end-stage renal disease - direct acting antiviral

Ethical Statement

The institutional ethics committee (IEC-SKIMS) cleared the study with reference number RP 86/2020. Informed written consent was obtained before inclusion.


Authors' Contributions

Conceptualization: A.A., A.S., M.W. Methodology, investigation, and original draft: A.A. Project administration and supervision: A.S. Data curation, visualization, and software: M.K., G.M.G. Initial draft: S.P. Resources: J.S. Data curation: H.D. Validation: N.A. All authors approved the final version.


Data Availability Statement

The data associated can be obtained from the corresponding author on a reasonable request.




Publication History

Received: 31 July 2022

Accepted: 03 October 2022

Article published online:
22 September 2023

© 2023. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003; 325 (03) 135-148
    CrossrefPubMedSearch in Google Scholar
  • 2 Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver Int 2016; 36 (Suppl. 01) 28-33
    CrossrefPubMedSearch in Google Scholar
  • 3 Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol 2016; 27 (08) 2238-2246
    CrossrefPubMedSearch in Google Scholar
  • 4 Martin P, Fabrizi F. Hepatitis C virus and kidney disease. J Hepatol 2008; 49 (04) 613-624
    CrossrefPubMedSearch in Google Scholar
  • 5 Takano S, Omata M, Ohto M, Satomura Y. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis. Hepatology 1993; 18 (02) 235-239
    CrossrefPubMedSearch in Google Scholar
  • 6 AASLD/IDA. HCV Guidance: Recommendations for testing, managing and treating hepatitis C; 2016. Accessed October 31, 2022, at: http://www.hcvguidance.org
  • 7 European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63 (01) 199-236
    CrossrefPubMedSearch in Google Scholar
  • 8 Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull 2015; 113 (01) 31-44
    CrossrefPubMedSearch in Google Scholar
  • 9 Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015; 385 (9973): 1124-1135
    CrossrefPubMedSearch in Google Scholar
  • 10 Goel A, Bhargava R, Rai P, Aggarwal R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: an Indian experience. Indian J Gastroenterol 2017; 36 (03) 227-234
    CrossrefPubMedSearch in Google Scholar
  • 11 Herzer K, Welzel TM, Spengler U. et al. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease. Transpl Int 2017; 30 (03) 243-255
    CrossrefPubMedSearch in Google Scholar
  • 12 Welzel TM, Petersen J, Herzer K. et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; 65 (11) 1861-1870
    CrossrefPubMedSearch in Google Scholar
  • 13 Goel A, Bhadauria DS, Kaul A. et al. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients. Indian J Gastroenterol 2017; 36 (02) 137-140
    CrossrefPubMedSearch in Google Scholar
  • 14 Kamar N, Marion O, Rostaing L. et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 2016; 16 (05) 1474-1479
    CrossrefPubMedSearch in Google Scholar
  • 15 Levey AS, Stevens LA, Schmid CH. et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150 (09) 604-612
    CrossrefPubMedSearch in Google Scholar
  • 16 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142 (06) 1293-1302.e4
    CrossrefPubMedSearch in Google Scholar
  • 17 Jasuja S, Gupta AK, Choudhry R. et al. Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital. Indian J Nephrol 2009; 19 (02) 62-67
    CrossrefPubMedSearch in Google Scholar
  • 18 Masoodi I, Singh C, Wani IA, Wani MM, Ahmed TI, Sheikh RY. Sero conversion of viral hepatitis among end stage renal disease patients on hemodialysis in Kashmir: results of a prospective study. Open Access Maced J Med Sci 2019; 7 (04) 587-593
    CrossrefPubMedSearch in Google Scholar
  • 19 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series☆ . J Hepatol 2020; 73 (05) 1170-1218
    CrossrefPubMedSearch in Google Scholar
  • 20 KDIGO CKD Guidelines. 2018 Accessed October 31, 2022, at: https://kdigo.org/guidelines/hepatitis-c-in-ckd/
    PubMed
  • 21 AASLD Guidelines Update. 2019 https://www.aasld.org/news/hcv-guidance-updates-recommendations-identification-and-management-chronic-hep-c
    PubMed
  • 22 Gaur N, Malhotra V, Agrawal D. et al. Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. J Clin Exp Hepatol 2020; 10 (03) 189-193
    CrossrefPubMedSearch in Google Scholar
  • 23 Taneja S, Duseja A, Mehta M. et al. Sofosbuvir and velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int 2021; 41 (04) 705-709
    CrossrefPubMedSearch in Google Scholar
  • 24 Borgia SM, Dearden J, Yoshida EM. et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol 2019; 71 (04) 660-665
    CrossrefPubMedSearch in Google Scholar
  • 25 De A, Roy A, Verma N. et al. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis. Nephrology (Carlton) 2022; 27 (01) 82-89
    CrossrefPubMedSearch in Google Scholar